Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis
- PMID: 23933938
- DOI: 10.5754/hge11421
Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis
Abstract
Background/aims: Vitamin E is one of the most promising treatments for non-alcoholic steatohepatitis (NASH). However, the long-term efficacy of this treatment remains unknown.
Methodology: We retrospectively examined 17 patients with biopsy-proven NASH who received vitamin E at a dose of 300 mg/day for >=2 yr, and underwent second liver biopsies after treatment. Variables were compared between patients with (group R) and without (group NR) fibrosis regression.
Results: The median interval between basal and second liver biopsies was 2.4 yr (range, 2.0-5.8 yr). Overall, transaminase activities, insulin resistance index, and hepatic fibrosis markers were significantly improved. Although histological steatosis, inflammation, and fibrosis did not change after treatment, liver fibrosis improved in seven patients (41.2%), progressed in five (29.4%), and remained unchanged in five (29.4%). At baseline, subjects in group R (n = 7) were more likely to have diabetes, insulin resistance, and severe fibrosis compared to those in group NR (n = 10). Lower NAFLD activity score and larger decrease of ALT and insulin resistance after treatment were observed in group R compared with group NR.
Conclusions: Two years or longer treatment can be expected to ameliorate NASH fibrosis, especially in those whose serum transaminase activities and insulin resistance can be improved.
Similar articles
-
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.Gastroenterology. 2008 Jul;135(1):100-10. doi: 10.1053/j.gastro.2008.03.078. Epub 2008 Apr 8. Gastroenterology. 2008. PMID: 18503774 Clinical Trial.
-
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.Am J Gastroenterol. 2005 May;100(5):1082-90. doi: 10.1111/j.1572-0241.2005.41583.x. Am J Gastroenterol. 2005. PMID: 15842582 Clinical Trial.
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol. 2003 Nov;98(11):2485-90. doi: 10.1111/j.1572-0241.2003.08699.x. Am J Gastroenterol. 2003. PMID: 14638353 Clinical Trial.
-
Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine.Altern Med Rev. 2002 Aug;7(4):276-91. Altern Med Rev. 2002. PMID: 12197781 Review.
Cited by
-
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.Pharmaceutics. 2023 Jul 16;15(7):1963. doi: 10.3390/pharmaceutics15071963. Pharmaceutics. 2023. PMID: 37514148 Free PMC article. Review.
-
Ameliorative effects of glycine on cobalt chloride-induced hepato-renal toxicity in rats.Animal Model Exp Med. 2023 Apr;6(2):168-177. doi: 10.1002/ame2.12315. Animal Model Exp Med. 2023. PMID: 37141004 Free PMC article.
-
Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.Cancers (Basel). 2022 Dec 20;15(1):23. doi: 10.3390/cancers15010023. Cancers (Basel). 2022. PMID: 36612019 Free PMC article. Review.
-
Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.Int J Mol Sci. 2022 Dec 19;23(24):16226. doi: 10.3390/ijms232416226. Int J Mol Sci. 2022. PMID: 36555867 Free PMC article. Review.
-
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2021 Dec 8;22(24):13219. doi: 10.3390/ijms222413219. Int J Mol Sci. 2021. PMID: 34948020 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical